Breast Cancer Pipeline Review, H2 2012


#146129

611pages

Global Markets Direct

$ 2500

In Stock

 

Breast Cancer Pipeline Review, H2 2012

 

Global Markets Directs, 'Breast Cancer Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Breast Cancer. Breast Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Breast Cancer.
  • A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Breast Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Breast Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents


Table of Contents 2
List of Tables 17
List of Figures 26
Introduction 27
Global Markets Direct Report Coverage 27
Breast Cancer Overview 28
Therapeutics Development 29
An Overview of Pipeline Products for Breast Cancer 29
Breast Cancer Therapeutics under Development by Companies 31
Breast Cancer Therapeutics under Investigation by Universities/Institutes 48
Late Stage Products 69
Comparative Analysis 69
Mid Clinical Stage Products 70
Comparative Analysis 70
Early Clinical Stage Products 71
Comparative Analysis 71
Discovery and Pre-Clinical Stage Products 72
Comparative Analysis 72
Breast Cancer Therapeutics Products under Development by Companies 73
Breast Cancer Therapeutics Products under Investigation by Universities/Institutes 97
Companies Involved in Breast Cancer Therapeutics Development 150
Bristol-Myers Squibb Company 150
Johnson & Johnson 151
Boehringer Ingelheim GmbH 152
F. Hoffmann-La Roche Ltd. 153
Kyowa Hakko Kirin Co., Ltd. 154
Celsion Corporation 155
Abbott Laboratories 156
Amgen Inc. 157
Sanofi-Aventis 158
Adherex Technologies Inc. 159
AstraZeneca PLC 160
Eli Lilly and Company 161
Viralytics Ltd. 162
GlaxoSmithKline plc 163
Bioniche Life Sciences, Inc. 164
Inovio Biomedical Corporation 165
Biotec Pharmacon ASA 166
Watson Pharmaceuticals, Inc. 167
Bavarian Nordic A/S 168
Isis Pharmaceuticals, Inc. 169
Daiichi Sankyo Company, Ltd 170
Merck & Co., Inc. 171
AbGenomics International, Inc. 172
A&G Pharmaceutical, Inc. 173
Oxford BioMedica plc 174
Generex Biotechnology Corporation 175
BioLineRx, Ltd. 176
Ipsen S.A. 177
Piramal Healthcare Limited 178
MediGene AG 179
Bio-Path Holdings, Inc. 180
BioSante Pharmaceuticals, Inc. 181
Histogen, Inc. 182
ZIOPHARM Oncology, Inc. 183
Millennium Pharmaceuticals, Inc. 184
Novartis AG 185
Aphios Corporation 186
Astellas Pharma Inc. 187
Cephalon, Inc. 188
Chong Kun Dang Pharmaceutical 189
Dong-A Pharmaceutical Co., Ltd. 190
Eisai Co., Ltd. 191
Gedeon Richter Plc. 192
GTx, Inc. 193
Pfizer Inc. 194
Sigma-Tau S.p.A. 195
Takara Holdings Inc. 196
Exelixis, Inc. 197
Menarini Group 198
Alfacell Corporation 199
Celgene Corporation 200
Bayer AG 201
Washington University School of Medicine 202
Access Pharmaceuticals, Inc. 203
Advaxis, Inc. 204
Neogenix Oncology Corporation 205
Alchemia Limited 206
GW Pharmaceuticals plc 207
Hana Biosciences, Inc. 208
Hollis-Eden Pharmaceuticals, Inc. 209
Celldex Therapeutics, Inc. 210
Momenta Pharmaceuticals, Inc. 211
ValiRx Plc 212
AEterna Zentaris Inc. 213
ImmunoCellular Therapeutics, Ltd. 214
IMMUNOMEDICS, INC 215
Lorus Therapeutics Inc 216
Basilea Pharmaceutica Ltd. 217
Bionomics Limited 218
MultiCell Technologies, Inc. 219
Neuren Pharmaceuticals Limited 220
Northwest Biotherapeutics, Inc. 221
Novogen Limited 222
Cleveland BioLabs, Inc. 223
Compugen Ltd. 224
Patrys Limited 225
Peregrine Pharmaceuticals, Inc. 226
Critical Outcome Technologies Inc. 227
Curis, Inc. 228
CytoGenix, Inc. 229
Medivation, Inc. 230
ADVENTRX Pharmaceuticals 231
Bionovo, Inc. 232
CSL Limited 233
Telik, Inc. 234
Zenotech Laboratories Limited 235
Oncogenex Pharmaceuticals, Inc. 236
Dendreon Corporation 237
ProMetic Life Sciences Inc. 238
TTY Biopharm Company Limited 239
Jiangsu Hengrui Medicine Co., Ltd. 240
Provectus Pharmaceuticals, Inc. 241
Synta Pharmaceuticals Corp. 242
Sareum Holdings plc 243
Oasmia Pharmaceutical AB 244
Algeta ASA 245
Raptor Pharmaceuticals Corp. 246
RXi Pharmaceuticals Corporation 247
NanoCarrier Co., Ltd. 248
Rexahn Pharmaceuticals, Inc. 249
Merrion Pharmaceuticals Plc 250
MabVax Therapeutics, Inc. 251
Antigen Express, Inc. 252
Cancer Research Technology Limited 253
Oryzon 254
PCI Biotech Holding ASA 255
Avanti Therapeutics 256
Wilex AG 257
Chipscreen Biosciences Ltd 258
Supratek Pharma Inc. 259
Biotecnol SA 260
Ambit Biosciences Corporation 261
Immupharma Plc 262
GANYMED Pharmaceuticals AG 263
Philogen S.p.A. 264
Phosphagenics Limited 265
Actis Biologics, Inc 266
Med Discovery SA 267
Glycotope GmbH 268
Alethia Biotherapeutics Inc. 269
GenSpera, Inc. 270
Ascenta Therapeutics, Inc. 271
Coronado Biosciences, Inc. 272
Hawthorn Pharmaceuticals, Inc. 273
MacroGenics, Inc. 274
Pervasis Therapeutics, Inc. 275
Antyra, Inc. 276
OncoMed Pharmaceuticals, Inc. 277
Vaccinex, Inc. 278
Pantarhei Bioscience BV 279
AlphaVax, Inc. 280
Quintessence Biosciences, Inc. 311
Sirnaomics, Inc. 312
Tigris Pharmaceuticals, Inc. 313
Cylene Pharmaceuticals, Inc. 314
Genelux Corporation 315
Lipopharma 316
Nereus Pharmaceuticals, Inc. 317
Viventia Biotechnologies Inc. 318
ZGene A/S 319
Nexgenix Pharmaceuticals, LLC 320
Viromed Co., Ltd. 321
Archer Biosciences, Inc 322
Amazon BioTech 323
Keystone Nano, Inc. 324
EndoCeutics, Inc. 325
Pierre Fabre Medicament 326
Advanced Cancer Therapeutics 327
Domainex Ltd. 328
Oncolix, Inc. 329
Cancer Therapeutics CRC Pty Ltd 330
EpiZyme, Inc. 331
Targa Therapeutics Corp. 332
BioProspecting NB, Inc. 333
RECEPTA Biopharma S.A. 334
ISU ABXIS Co.,Ltd. 335
Bioo Therapeutics 336
Jiangsu Kanion Pharmaceutical Co., Ltd. 337
Vaxonco 338
BHR Pharma, LLC. 339
Pacific Northwest Biotechnology, LLC 340
Sentinel Oncology Limited 341
Nuvilex, Inc. 342
Celtic Pharmaceutical Holdings L.P. 343
Gliknik, Inc. 344
DEKK-TEC, Inc. 345
Regulon Inc. 346
ImQuest Life Sciences 347
Gradalis Inc. 348
Epeius Biotechnologies Corporation 349
Oncozyme Pharma Inc. 350
Ampio Pharmaceuticals, Inc. 351
CytomX, LLC. 352
Breast Cancer Therapeutics Assessment 353
Assessment by Monotherapy Products 353
Assessment by Combination Products 354
Assessment by Route of Administration 355
Assessment by Molecule Type 357
Drug Profiles 359
eribulin mesylate - Drug Profile 359
Product Description 359
Mechanism of Action 359
R&D Progress 359
denosumab - Drug Profile 361
Product Description 361
Mechanism of Action 361
R&D Progress 361
sorafenib tosylate - Drug Profile 363
Product Description 363
Mechanism of Action 363
R&D Progress 363
pertuzumab - Drug Profile 365
Product Description 365
Mechanism of Action 365
R&D Progress 365
exemestane - Drug Profile 403
Product Description 403
Mechanism of Action 403
R&D Progress 403
Acolbifene - Drug Profile 507
Product Description 507
Mechanism of Action 507
R&D Progress 507
Metformin + Taxane - Drug Profile 508
Product Description 508
Mechanism of Action 508
R&D Progress 508
Breast Cancer Therapeutics Drug Profile Updates 509
Breast Cancer Therapeutics Discontinued Products 542
Breast Cancer Therapeutics - Dormant Products 553
Breast Cancer Product Development Milestones 601
Featured News & Press Releases 601
Oct 02, 2012: Merrimack Pharma Presents Phase I Study Results Of MM-111 At European Society for Medical Oncology 2012 601
Oct 02, 2012: Merrimack Pharma Presents Phase I Study Of MM-121 At European Society For Medical Oncology 2012 602
Oct 01, 2012: Celsion Presents Phase I/II Study Data Of ThermoDox At 2012 Congress For European Society Of Medical Oncology 603
Oct 01, 2012: New Vaccinia Virus Shows Potential For Treating Triple-Negative Breast Cancer 604
Oct 01, 2012: MethylGene Presents Clinical Data On MGCD265 At European Society For Medical Oncology 2012 Congress 605
Oct 01, 2012: Roche Announces Final Results From Phase III HERA Trial Of Herceptin In Early-stage HER2-positive Breast Cancer 606
Sep 28, 2012: COTI To Present Data On New Mechanism Of Action Of COTI-2 At 'Discovery On Target: Targeting PI3K Pathways' 607
Sep 24, 2012: biOasis Announces Positive Preliminary Histopathology Results Of Herceptin BT2111 Program 607
Sep 24, 2012: Navidea Biopharma Provides NDA Update For Lymphoseek 608
Sep 20, 2012: Navidea Presents Lymphoseek Phase III Meta-Analysis Data At 32nd Congress Of European Society Of Surgical Oncology 609
 

Appendix 610
Methodology 610
Coverage 610
Secondary Research 610
Primary Research 610
Expert Panel Validation 610
Contact Us 611
Disclaimer 611


Number of Products Under Development for Breast Cancer, H2 2012 29
Products under Development for Breast Cancer Comparative Analysis, H2 2012 30
Number of Products under Development by Companies, H2 2012 32
Number of Products under Development by Companies, H2 2012 (Contd..1) 33
Number of Products under Development by Companies, H2 2012 (Contd..2) 34
Number of Products under Development by Companies, H2 2012 (Contd..3) 35
Number of Products under Development by Companies, H2 2012 (Contd..4) 36
Number of Products under Development by Companies, H2 2012 (Contd..5) 37
Number of Products under Development by Companies, H2 2012 (Contd..6) 38
Number of Products under Development by Companies, H2 2012 (Contd..7) 39
Number of Products under Development by Companies, H2 2012 (Contd..8) 40
Number of Products under Development by Companies, H2 2012 (Contd..9) 41
Number of Products under Development by Companies, H2 2012 (Contd..10) 42
Number of Products under Development by Companies, H2 2012 (Contd..11) 43
Number of Products under Development by Companies, H2 2012 (Contd..12) 44
Number of Products under Development by Companies, H2 2012 (Contd..13) 45
Number of Products under Development by Companies, H2 2012 (Contd..14) 46
Number of Products under Development by Companies, H2 2012 (Contd..15) 47
Number of Products under Investigation by Universities/Institutes, H2 2012 49
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 50
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 51
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 52
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 53
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 54
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 55
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 56
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 57
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 58
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 59
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 60
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 61
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 62
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 63
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 64
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 65
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 66
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 67
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 68
Comparative Analysis by Late Stage Development, H2 2012 69
Comparative Analysis by Mid Clinical Stage Development, H2 2012 70
Comparative Analysis by Early Clinical Stage Development, H2 2012 71
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 72
Products under Development by Companies, H2 2012 73
Products under Development by Companies, H2 2012 (Contd..1) 74
Products under Development by Companies, H2 2012 (Contd..2) 75
Products under Development by Companies, H2 2012 (Contd..3) 76
Products under Development by Companies, H2 2012 (Contd..4) 77
Products under Development by Companies, H2 2012 (Contd..5) 78
Products under Development by Companies, H2 2012 (Contd..6) 79
Products under Development by Companies, H2 2012 (Contd..7) 80
Products under Development by Companies, H2 2012 (Contd..8) 81
Products under Development by Companies, H2 2012 (Contd..9) 82
Products under Development by Companies, H2 2012 (Contd..10) 83
Products under Development by Companies, H2 2012 (Contd..11) 84
Products under Development by Companies, H2 2012 (Contd..12) 85
Products under Development by Companies, H2 2012 (Contd..13) 86
Products under Development by Companies, H2 2012 (Contd..14) 87
Products under Development by Companies, H2 2012 (Contd..15) 88
Products under Development by Companies, H2 2012 (Contd..16) 89
Products under Development by Companies, H2 2012 (Contd..17) 90
Products under Development by Companies, H2 2012 (Contd..18) 91
Products under Development by Companies, H2 2012 (Contd..19) 92
Products under Development by Companies, H2 2012 (Contd..20) 93
Products under Development by Companies, H2 2012 (Contd..21) 94
Products under Development by Companies, H2 2012 (Contd..22) 95
Products under Development by Companies, H2 2012 (Contd..23) 96
Products under Investigation by Universities/Institutes, H2 2012 97
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 98
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 99
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 100
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 101
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 102
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 103
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 104
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 105
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 106
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 107
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 108
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 109
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 110
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 111
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 112
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 113
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 114
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 115
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 116
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 117
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 118
Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 119
Products under Investigation by Universities/Institutes, H2 2012 (Contd..23) 120
Products under Investigation by Universities/Institutes, H2 2012 (Contd..24) 121
Products under Investigation by Universities/Institutes, H2 2012 (Contd..25) 122
Products under Investigation by Universities/Institutes, H2 2012 (Contd..26) 123
Products under Investigation by Universities/Institutes, H2 2012 (Contd..27) 124
Products under Investigation by Universities/Institutes, H2 2012 (Contd..28) 125
Products under Investigation by Universities/Institutes, H2 2012 (Contd..29) 126
Products under Investigation by Universities/Institutes, H2 2012 (Contd..30) 127
Products under Investigation by Universities/Institutes, H2 2012 (Contd..31) 128
Products under Investigation by Universities/Institutes, H2 2012 (Contd..32) 129
Products under Investigation by Universities/Institutes, H2 2012 (Contd..33) 130
Products under Investigation by Universities/Institutes, H2 2012 (Contd..34) 131
Products under Investigation by Universities/Institutes, H2 2012 (Contd..35) 132
Products under Investigation by Universities/Institutes, H2 2012 (Contd..36) 133
Products under Investigation by Universities/Institutes, H2 2012 (Contd..37) 134
Products under Investigation by Universities/Institutes, H2 2012 (Contd..38) 135
Products under Investigation by Universities/Institutes, H2 2012 (Contd..39) 136
Products under Investigation by Universities/Institutes, H2 2012 (Contd..40) 137
Products under Investigation by Universities/Institutes, H2 2012 (Contd..41) 138
Products under Investigation by Universities/Institutes, H2 2012 (Contd..42) 139
Products under Investigation by Universities/Institutes, H2 2012 (Contd..43) 140
Products under Investigation by Universities/Institutes, H2 2012 (Contd..44) 141
Products under Investigation by Universities/Institutes, H2 2012 (Contd..45) 142
Products under Investigation by Universities/Institutes, H2 2012 (Contd..46) 143
Products under Investigation by Universities/Institutes, H2 2012 (Contd..47) 144
Products under Investigation by Universities/Institutes, H2 2012 (Contd..48) 145
Products under Investigation by Universities/Institutes, H2 2012 (Contd..49) 146
Products under Investigation by Universities/Institutes, H2 2012 (Contd..50) 147
Products under Investigation by Universities/Institutes, H2 2012 (Contd..51) 148
Products under Investigation by Universities/Institutes, H2 2012 (Contd..52) 149
Bristol-Myers Squibb Company, H2 2012 150
Johnson & Johnson, H2 2012 151
Boehringer Ingelheim GmbH, H2 2012 152
F. Hoffmann-La Roche Ltd., H2 2012 153
Kyowa Hakko Kirin Co., Ltd., H2 2012 154
Celsion Corporation, H2 2012 155
Abbott Laboratories, H2 2012 156
Amgen Inc., H2 2012 157
Sanofi-Aventis, H2 2012 158
Adherex Technologies Inc., H2 2012 159
AstraZeneca PLC, H2 2012 160
Eli Lilly and Company, H2 2012 161
Viralytics Ltd., H2 2012 162
GlaxoSmithKline plc, H2 2012 163
Bioniche Life Sciences, Inc., H2 2012 164
Inovio Biomedical Corporation, H2 2012 165
Biotec Pharmacon ASA, H2 2012 166
Watson Pharmaceuticals, Inc., H2 2012 167
Bavarian Nordic A/S, H2 2012 168
Isis Pharmaceuticals, Inc., H2 2012 169
Daiichi Sankyo Company, Ltd, H2 2012 170
Merck & Co., Inc., H2 2012 171
AbGenomics International, Inc., H2 2012 172
A&G Pharmaceutical, Inc., H2 2012 173
Oxford BioMedica plc, H2 2012 174
Generex Biotechnology Corporation, H2 2012 175
BioLineRx, Ltd., H2 2012 176
Ipsen S.A., H2 2012 177
Piramal Healthcare Limited, H2 2012 178
MediGene AG, H2 2012 179
Bio-Path Holdings, Inc., H2 2012 180
BioSante Pharmaceuticals, Inc., H2 2012 181
Histogen, Inc., H2 2012 182
ZIOPHARM Oncology, Inc., H2 2012 183
Millennium Pharmaceuticals, Inc., H2 2012 184
Novartis AG, H2 2012 185
Aphios Corporation, H2 2012 186
Astellas Pharma Inc., H2 2012 187
Cephalon, Inc., H2 2012 188
Chong Kun Dang Pharmaceutical, H2 2012 189
Dong-A Pharmaceutical Co., Ltd., H2 2012 190
Eisai Co., Ltd., H2 2012 191
Gedeon Richter Plc., H2 2012 192
GTx, Inc., H2 2012 193
Pfizer Inc., H2 2012 194
Sigma-Tau S.p.A., H2 2012 195
Takara Holdings Inc., H2 2012 196
Exelixis, Inc., H2 2012 197
Menarini Group, H2 2012 198
Alfacell Corporation, H2 2012 199
Celgene Corporation, H2 2012 200
Bayer AG, H2 2012 201
Washington University School of Medicine, H2 2012 202
Access Pharmaceuticals, Inc., H2 2012 203
Advaxis, Inc., H2 2012 204


Number of Products under Development for Breast Cancer, H2 2012 29
Products under Development for Breast Cancer Comparative Analysis, H2 2012 30
Products under Development by Companies, H2 2012 31
Products under Investigation by Universities/Institutes, H2 2012 48
Late Stage Products, H2 2012 69
Mid Clinical Stage Products, H2 2012 70
Early Clinical Stage Products, H2 2012 71
Discovery and Pre-Clinical Stage Products, H2 2012 72
Assessment by Monotherapy Products, H2 2012 353
Assessment by Combination Products, H2 2012 354
Assessment by Route of Administration, H2 2012 355
Assessment by Stage and Route of Administration, H2 2012 356
Assessment by Molecule Type, H2 2012 357
Assessment by Stage and Molecule Type, H2 2012 358